Heart Failure


The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.

Preterm Birth Associated with Increased Heart Failure Risk Throughout Adulthood

April 09, 2021

An analysis of nearly 4.2 million patients from a birth registry indicates being born preterm was linked to a significantly higher risk of developing heart failure during childhood and a 42% greater risk of heart failure in adulthood.

GLS-Guided Therapy Could Reduce Impact of Cardiotoxicity from Chemotherapy

February 02, 2021

The SUCCOUR trial indicates GLS-guided cardioprotective therapy could be more effective at reducing the impact of cancer therapy-related cardiac dysfunction and incidence of cardiotoxicity than LVEF-guided therapy in patients exposed to anthracyclines.

FDA Approves Vericiguat (Verquvo) for Treatment of Heart Failure

January 20, 2021

The US FDA has approved vericiguat (Verquvo) for reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in patients with HFrEF.

AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program

November 18, 2020

TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.

Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials

November 17, 2020

Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.